Solutions

Online Inquiry

Global Services. (Creative Biolabs Authorized)

CAR-T Persistence Bioanalysis Service by Immediate PCR/Flow Cytometry

Online Inquiry

Background Service What We Can Offer Workflow Highlights FAQs Contact

Despite the success of CAR-T therapy in hematologic malignancies, achieving durable efficacy in solid tumors remains challenged by poor T cell persistence, influenced by factors like immunosuppressive microenvironments, tonic signaling, and suboptimal engraftment. Creative Biolabs' CAR-T Persistence Bioanalysis Service by Immediate PCR/Flow Cytometry directly addresses these hurdles. This integrated solution provides rapid, sensitive quantification of CAR transgene copies via Immediate PCR and detailed phenotypic profiling of CAR-T subsets via multiparametric flow cytometry. The key advantage is the delivery of correlative, high-resolution data on both CAR-T magnitude and functional state, enabling clients to precisely monitor persistence kinetics, evaluate novel engineering strategies, and make data-driven decisions to enhance therapeutic durability and clinical outcomes.

Introduction

CAR-T cell therapy has demonstrated remarkable success in treating hematological malignancies, yet its efficacy in solid tumors remains limited, in part due to inadequate persistence of adoptively transferred T cells. Persistence, defined as the long-term survival and functional maintenance of CAR-T cells post-infusion, is a critical determinant of therapeutic outcome, particularly in solid tumor microenvironments characterized by immunosuppression, metabolic stress, and poor T cell trafficking. Therefore, precise and dynamic monitoring of CAR-T cell persistence is essential to evaluate therapeutic performance and guide iterative improvements in cell engineering, manufacturing, and patient conditioning.

Fig.1 Pivotal avenues to optimize CAR-T cell persistence in solid tumors. (OA Literature) Fig.1 Core approaches to enhance CAR-T cell persistence.¹

CAR-T Persistence Bioanalysis Service by Immediate PCR/Flow Cytometry at Creative Biolabs

Creative Biolabs provides an integrated bioanalytical platform that translates complex cellular data into actionable clinical insights. Our method combines definitive molecular quantification with immediate protein-level analysis to deliver the granular, submission-ready data essential for contemporary regulatory filings.

What We Can Offer

Our integrated bioanalytical service empowers CAR-T therapy development with precise, multi-dimensional data. We offer a synergistic suite of solutions to quantify, characterize, and understand CAR-T cell behavior in vivo through the following key capabilities:

Featured services of CAR-T persistence bioanalysis service by immediate PCR/Flow cytometry at Creative Biolabs. (Creative Biolabs Original)

Our Service Process

Required Starting Materials:

Target Material: peripheral blood or bone marrow aspirates.
Genetic Information: CAR construct sequence (scFv and co-stimulatory domains) for custom primer/probe design.

Key Steps:

Workflow of CAR-T persistence bioanalysis service by immediate PCR/Flow cytometry at Creative Biolabs. (Creative Biolabs Original)

Final Deliverables:

Comprehensive Bioanalytical Report.
Persistence Kinetic Curves: Graphical representation of expansion, persistence, and exhaustion markers.

Key Advantages

End-to-End Bioanalytical Solutions: We provide a comprehensive suite of services, encompassing initial therapeutic sequence evaluation and custom reagent development, through to large-cohort clinical monitoring across extended timelines.
Tailored Assay Optimization: Our experts refine codon usage and enhance probe specificity to guarantee absolute discrimination from endogenous T-cell receptors and unrelated microbial genomes.
Adaptive Service Models: We support both retrospective batch analysis and prospective real-time monitoring protocols, enabling either strategic research review or urgent clinical safety assessments.

FAQs

Q1: How does ddPCR compare to traditional qPCR for long-term monitoring?

A1: ddPCR provides absolute quantification without a standard curve, making it significantly more sensitive for detecting low-level persistence (MRD) and more reproducible across different clinical sites.

Q2: Can you distinguish between different CAR-T products in a single sample?

A2: Yes, through our multiplexed probe technology, we can design specific assays that distinguish between different CAR constructs or verify specific co-stimulatory domains.

Q3: What is the benefit of adding Flow Cytometry to the molecular PCR data?

A3: While PCR tells you the "how many," flow cytometry tells you the "what." It provides essential data on the CD4/CD8 phenotype and exhaustion status that PCR cannot capture.

Why Choose Us?

Our proprietary "Multiplex-Context" platform integrates highly reproducible, site-transferable ddPCR with immediate flow cytometry phenotyping. This hybrid approach delivers absolute quantification and cellular context critical for analysis. We specialize in identifying the "Day 28 Landmark," a key early predictor of long-term therapeutic efficacy and progression-free survival, providing you with decisive, actionable data.

Customer Reviews

"Combining immediate T-cell phenotyping with ddPCR provided critical, real-time insights into CD8+ expansion kinetics during the pivotal initial post-infusion phase."

— Dr. Jul*** Dei.

"Our work with Creative Biolabs' Persistence Bioanalysis successfully tracked CAR-T constructs at MRD levels previously undetectable by standard flow cytometry."

— Dr. Mar*** Son.

"Generating absolute cell counts and phenotypic data from little blood sample was instrumental for our pediatric trial and demonstrated outstanding inter-laboratory consistency."

— Prof. Eli*** Van.

How to contact us?

Precisely track the in vivo longevity and kinetics of your engineered T cells with our validated hybrid qPCR and flow cytometry platform. To discuss a customized analysis plan and receive a competitive project quote, please contact our dedicated cell therapy analytics team for a confidential consultation.

Reference

Wittling, Megen C et al. "Strategies for Improving CAR T Cell Persistence in Solid Tumors." Cancers vol. 16,16 2858. Distributed under Open Access License CC BY 4.0, without modification. https://doi.org/10.3390/cancers16162858

All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.